Virginia Clark

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

Vlad Ratziu, Stephen A. Harrison, Sven Francque et al. · Gastroenterology · 2016 · 993 citations · Full text

Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes

Fernando Bril, Srilaxmi Kalavalapalli, Virginia Clark et al. · Clinical Gastroenterology and Hepatology · 2017 · 194 citations

Metabolic Syndrome, Diabetes Management, Hepatology +10

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

David Jones, Pol Boudes, Mark G. Swain et al. · ˜The œLancet. Gastroenterology & hepatology · 2017 · 181 citations

Molecular Pharmacology, Selective Ppar-δ Agonist, Hepatology +11

Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid

Cynthia Levy, Joy Peter, David R. Nelson et al. · Alimentary Pharmacology & Therapeutics · 2010 · 175 citations · Full text

Gastroenterology, Pharmacotherapy, Ursodeoxycholic Acid +18

Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes

Fernando Bril, Michael J. McPhaul, Michael P. Caulfield et al. · Diabetes Care · 2019 · 174 citations